JAMA Network
About The Study: The findings of this study suggest that body mass index and obesity prevalence in the U.S. decreased in 2023 for the first time in more than a decade. The most notable decrease was in the South, which had the highest observed per capita glucagon-like peptide 1 receptor agonist (GLP-1RA) dispensing rate. However, dispensing does not necessarily mean uptake, and the South also experienced disproportionately high COVID-19 mortality among individuals with obesity.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
